PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival.
PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival.
复制标题
DOI：
10.18632/oncotarget.5028
复制
发表时间：
2015-10-20
期刊：
影响因子：
--
通讯作者：
Zhang L
中科院分区：
文献类型：
--
作者：
Fang W;Hong S;Chen N;He X;Zhan J;Qin T;Zhou T;Hu Z;Ma Y;Zhao Y;Tian Y;Yang Y;Xue C;Tang Y;Huang Y;Zhao H;Zhang L
程序性细胞死亡配体1（PD - L1）和驱动基因突变常见于非小细胞肺癌（NSCLC）。然而，在EB病毒（EBV）相关的肺淋巴上皮瘤样癌（LELC）中，PD - L1过表达的患病率及其预后价值仍知之甚少。
共纳入214例NSCLC患者和113例接受手术治疗的肺LELC患者。用PD - L1抗体对石蜡包埋的肿瘤切片进行染色。分析了PD - L1表达与临床病理特征以及生存结果之间的相关性。
NSCLC中PD - L1过表达的频率为51.4%。常见驱动基因突变与PD - L1过表达之间未观察到显著关联。值得注意的是，肺LELC中PD - L1的阳性率为74.3%。与低PD - L1表达相比，高PD - L1表达与无病生存期（DFS）受损相关（p = 0.008）。多因素分析表明，PD - L1表达水平、N分期和M分期是DFS的独立预后因素。N分期和M分期而非PD - L1表达水平与总生存期（OS）显著相关。
在NSCLC中，PD - L1过表达与常见驱动基因突变无关。肺LELC中PD - L1表达的发生率非常高。在手术切除的肺LELC中，PD - L1是DFS的不良预后因素。这些发现可能为这种病毒相关肺癌的免疫靶向治疗提供理论依据。
Programmed cell death-ligand 1 (PD-L1) and driver mutations are commonly seen in non-small-cell lung cancer (NSCLC). However, the prevelance of PD-L1 over-expression and its prognostic value in Epstein–Barr virus (EBV) associated pulmonary lymphoepithelioma-like carcinoma (LELC) remains poorly understood. A total of 214 NSCLC patients and 113 surgically treated pulmonary LELC patients were included. Paraffin-embedded tumor sections were stained with PD-L1 antibody. Correlations between PD-L1 expression and clinicopathological features as well as survival outcomes were analyzed. The frequency of PD-L1 over-expression in NSCLC was 51.4%. No significant association was observed between common driver mutations and PD-L1 over-expression. Remakably, the positive rate of PD-L1 in pulmonary LELC was 74.3%. High PD-L1 expression was associated with impaired diseas-free survival (DFS) compared with low PD-L1 expression (p = 0.008). Multivariate analysis shows that PD-L1 expression level, N stage and M stage were independent prognostic factors for DFS. N stage and M stage but not PD-L1 expression level were significantly associated with overall survival (OS). PD-L1 over-expression was not related to common driver mutations in NSCLC. Pulmonary LELC have remarkably high incidence of PD-L1 expression. PD-L1 was a negative prognostic factor for DFS in surgically resected pulmonary LELC. These findings may provide a rationale for immunotarget therapy in this virus-associated lung cancer.